BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 9467046)

  • 21. Alpha(human leukocyte)-interferon as treatment for non-small cell carcinoma of the lung: a phase II trial.
    Sarna G; Figlin R; Callaghan M
    J Biol Response Mod; 1983; 2(4):343-7. PubMed ID: 6315898
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cancer immunotherapy with low-dose interleukin-2 subcutaneous administration: potential efficacy in most solid tumor histotypes by a concomitant treatment with the pineal hormone melatonin.
    Lissoni P; Barni S; Ardizzoia A; Olivini G; Brivio F; Tisi E; Tancini G; Characiejus D; Kothari L
    J Biol Regul Homeost Agents; 1993; 7(4):121-5. PubMed ID: 8023699
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Two phase I studies of low dose recombinant human IL-12 with Melan-A and influenza peptides in subjects with advanced malignant melanoma.
    Cebon J; Jäger E; Shackleton MJ; Gibbs P; Davis ID; Hopkins W; Gibbs S; Chen Q; Karbach J; Jackson H; MacGregor DP; Sturrock S; Vaughan H; Maraskovsky E; Neumann A; Hoffman E; Sherman ML; Knuth A
    Cancer Immun; 2003 Jul; 3():7. PubMed ID: 12862418
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [A phase I study of recombinant interleukin 2 (S6820)].
    Takaku F
    Gan To Kagaku Ryoho; 1988 Dec; 15(12):3271-6. PubMed ID: 3058043
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical drug development: an analysis of phase II trials, 1970-1985.
    Marsoni S; Hoth D; Simon R; Leyland-Jones B; De Rosa M; Wittes RE
    Cancer Treat Rep; 1987 Jan; 71(1):71-80. PubMed ID: 3791270
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I trial of recombinant human gamma-interferon and recombinant human tumor necrosis factor in patients with advanced gastrointestinal cancer.
    Abbruzzese JL; Levin B; Ajani JA; Faintuch JS; Saks S; Patt YZ; Edwards C; Ende K; Gutterman JU
    Cancer Res; 1989 Jul; 49(14):4057-61. PubMed ID: 2500234
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Phase-II-study with vindesine (desacetyl-vinblastine-amide-sulfate) in advanced malignant diseases].
    Goldhirsch A; Beer M; Sonntag RW; Tschopp L; Cavalli F; Ryssel HJ; Brunner KW
    Schweiz Med Wochenschr; 1980 Jul; 110(27-28):1063-7. PubMed ID: 7423151
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II evaluation of metoprine in patients with non-small-cell lung carcinoma.
    Lynch GR; Gralla RJ; Kelsen DP; Casper ES; Stoopler MB; Golbey RB
    Cancer Clin Trials; 1981; 4(3):273-6. PubMed ID: 6974611
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II evaluation of bisantrene in patients with advanced non-small cell lung carcinoma.
    Feld R; Evans WK; Shepherd FA; Deboer G; Ottema B
    Cancer Treat Rep; 1985 Feb; 69(2):209-10. PubMed ID: 3971392
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II study of divided-dose vinblastine in non-small cell bronchogenic carcinoma.
    Schulman P; Budman DR; Vinciguerra V; Weiselberg L; Abrams S; Degnan T
    Cancer Treat Rep; 1982 Jan; 66(1):171-2. PubMed ID: 7053253
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I clinical studies of antineoplaston A5 injections.
    Burzynski SR; Kubove E; Burzynski B
    Drugs Exp Clin Res; 1987; 13 Suppl 1():37-43. PubMed ID: 3569014
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase I study of recombinant human interleukin-4 administered by the intravenous and subcutaneous route in patients with advanced cancer: immunological studies.
    Ghosh AK; Smith NK; Prendiville J; Thatcher N; Crowther D; Stern PL
    Eur Cytokine Netw; 1993; 4(3):205-11. PubMed ID: 8218945
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II trial of retinol in patients with advanced cancer.
    Goodman GE
    Cancer Treat Rep; 1986 Aug; 70(8):1023-4. PubMed ID: 3731149
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systemic administration of recombinant methionyl human interleukin-2 (Ala 125) to cancer patients: clinical results.
    Sarna GP; Figlin RA; Pertcheck M; Altrock B; Kradjian SA
    J Biol Response Mod; 1989 Feb; 8(1):16-24. PubMed ID: 2784163
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recombinant leukocyte alpha interferon in advanced ovarian carcinoma.
    Niloff JM; Knapp RC; Jones G; Schaetzl EM; Bast RC
    Cancer Treat Rep; 1985; 69(7-8):895-6. PubMed ID: 4016797
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase II study of subcutaneous recombinant human interleukin-4 in metastatic renal cell carcinoma.
    Stadler WM; Rybak ME; Vogelzang NJ
    Cancer; 1995 Nov; 76(9):1629-33. PubMed ID: 8635068
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I study of recombinant human tumor necrosis factor-alpha in patients with advanced malignancies.
    Bartsch HH; Nagel GA; Mull R; Flener R; Pfizenmaier K
    Mol Biother; 1988; 1(1):21-9. PubMed ID: 3267369
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II study of caracemide in advanced or recurrent non-small cell lung cancer.
    Belani CP; Eisenberger M; Van Echo D; Hiponia D; Aisner J
    Cancer Treat Rep; 1987 Nov; 71(11):1099-100. PubMed ID: 2824047
    [No Abstract]   [Full Text] [Related]  

  • 39. Phase I clinical trial of an MAF-containing lymphoblastoid cell line supernatant.
    Reynolds RD; McEntire JE; Rodes ND; Dunn PA; Walter J; Doyle MK; Anson NO; Garcia A; Oxenhandler RW; Khojasteh A
    J Biol Response Mod; 1986 Apr; 5(2):129-39. PubMed ID: 3525761
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized trial of low doses of alpha interferon in patients with breast cancer.
    Laszlo J; Hood L; Cox E; Goodwin B
    J Biol Response Mod; 1986 Jun; 5(3):206-10. PubMed ID: 3723137
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.